H.C. Wainwright assigns Buy rating to Nurix stock with 60% approval probability for NX-5948

Investing.com  |  Editor Ahmed Abdulazez Abdulkadir

Published Dec 12, 2024 02:08

H.C. Wainwright assigns Buy rating to Nurix stock with 60% approval probability for NX-5948

On Wednesday, H.C. Wainwright adjusted its outlook on Nurix Therapeutics (NASDAQ:NRIX), increasing the 12-month price target to $35 from the previous $30, while maintaining a Buy rating on the stock. This adjustment follows Nurix's presentation of updated clinical data at the American Society of Hematology (ASH) 2024 annual meeting, showcasing promising results from its Phase 1a/1b trial of NX-5948 in patients with relapsed or refractory B-cell malignancies.

Nurix's oral Bruton's tyrosine kinase (BTK) degrader, NX-5948, is under evaluation for its effectiveness in treating chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The data presented revealed a 75.5% objective response rate (ORR) in 49 evaluable CLL patients after eight weeks and an 84.2% ORR in 38 evaluable CLL patients after 16 weeks. These findings indicate that patients not only responded to the treatment but also experienced deepening responses over time.

The safety profile of NX-5948 was also discussed, with a small percentage of patients experiencing Grade 3 or higher neutropenia, thrombocytopenia, anemia, and hypertension. Only one patient with pre-existing atrial fibrillation reported a Grade 1 atrial fibrillation. These results suggest a favorable safety and tolerability profile for the drug candidate.

The company plans to move NX-5948 into pivotal trials for patients who have previously been treated with BTK inhibitors and BCL2 inhibitors in 2025. In light of the recent data, H.C. Wainwright has increased the probability of approval for NX-5948 to 60%, up from the previous estimate of 50%.

The firm's increased confidence in the potential approval and commercial success of NX-5948 underpins the raised price target and continued Buy rating for Nurix.

The latest clinical outcomes, particularly the comparison to the response rates from previous conferences, have been a significant factor in the revised valuation of the company's shares.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes